| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10915969 | Nuclear Medicine and Biology | 2015 | 7 Pages |
Abstract
To the best of our knowledge, this study represents the first comparison of 64Cu-labeled DOTA and NODAGA immunoconjugates in vivo. Our results show favorable in vivo performance for 64Cu-NODAGA-mAb7 which builds upon previous data on our hybrid mAb7 imaging agent by increasing the detection sensitivity for metastatic prostate tumors, as well as for other types of cancer that express EpCAM.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sukhen C. Ghosh, Kenneth L. Pinkston, Holly Robinson, Barrett R. Harvey, Nathaniel Wilganowski, Karen Gore, Eva M. Sevick-Muraca, Ali Azhdarinia,